Phase 3 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form
- People who have been diagnosed with classic follicular lymphoma, confirmed through tissue testing, according to the 2022 WHO classification system
- People whose physical functioning is rated at a certain level (ECOG score of 0 to 2), meaning they are fully active to capable of basic self-care (confirm with trial site)
- People who have not yet received any systemic (whole-body) treatment for their lymphoma
- People whose lymphoma meets at least one specific medical standard indicating that systemic treatment is needed (called GELF criteria — confirm with trial site)
- People whose lymphoma can be detected by a specific type of scan (FDG-PET) and measured
- People whose lymphoma is at stage II, III, or IV and has a risk score between 2 and 5 on a scale called FLIPI — this applies to the Phase III part of the trial only
- People whose liver, blood, kidney, and heart are functioning adequately
Who may not be able to join:
- People diagnosed with a specific subtype called follicular large B-cell lymphoma, or those showing signs that their lymphoma may have changed into a more aggressive form
- People who have a medical reason they cannot receive certain chemotherapy combinations used in this trial (BR, RCVP, or R-CHOP)
- People who have, or have had, lymphoma affecting the brain or spinal cord
- People who have had a significant brain or nervous system condition in the past year, currently have symptoms from such a condition, or where the treating doctor believes it could affect safety monitoring in the trial
- People with more than 5,000 lymphoma cells circulating in their blood
- People with an active or uncontrolled infection (including certain viral infections such as EBV) that requires systemic treatment and poses unacceptable risk during the trial — specific rules around recent COVID-19 infection also apply (confirm with trial site)
- People with a known history of a serious immune system condition called hemophagocytic lymphohistiocytosis or macrophage activation syndrome (HLH/MAS)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chan Cheah, MBBS FRACP FRCPA DMSc, Sir Charles Gairdner Hospital (SCGH)
Phone: 1-877-240-9479
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
SRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs; SRI Primary: Determination of the recommended Phase III dose (RP3D); Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy; Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.